Last reviewed · How we verify

NCT00304811

Vancomycin Versus Vancomycin Plus Gentamycin For Treating Bacteremic Infection Due to Methicillin-Resistant Staphylococcus Aureus (MRSA)

Completed Phase 4 Last updated 25 September 2009
What this trial tests

Phase 4 trial testing Vancomycin in Staphylococcus Aureus in 160 participants. Completed in 1 January 2007.

Timeline
1 January 2006
Primary endpoint
1 January 2007
1 January 2007

Quick facts

Lead sponsorMichael E. DeBakey VA Medical Center
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Enrollment160
Start date1 January 2006
Primary completion1 January 2007
Estimated completion1 January 2007
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Michael E. DeBakey VA Medical Center

Who can join

Adults 18 to 64, any sex, with Staphylococcus Aureus. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to compare the outcome of treatment for bacteremic MRSA infection with vancomycin alone, vancomycin plus gentamicin, vancomycin plus rifampin, and vancomycin plus gentamicin and rifampin.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Vancomycin

Trials testing the same drug.

Other recruiting trials for Staphylococcus Aureus

Currently open trials in the same condition.

Other Michael E. DeBakey VA Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00304811.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing